Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients

Clinical cancer research : an official journal of the American Association for Cancer Research

Volumn 20, Issue 17, 2014, Pages 4471-4477

  Medioni, Jacques ^a   Deplanque, Gael ^a   Ferrero, Jean Marc ^a   Maurina, Tristan ^a   Rodier, Jean Michel P ^a   Raymond, Eric ^a   Allyon, Jorge ^a   Maruani, Gerard ^a   Houillier, Pascal ^a   Mackenzie, Sarah ^a   Renaux, Stephanie ^a   Dufour Lamartinie, Jean Francois ^a   Elaidi, Reza ^a   Lerest, Celine ^a   Oudard, Stephane ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYNE; ANTINEOPLASTIC AGENT; CALCITRIOL RECEPTOR; COLECALCIFEROL; DOCETAXEL; INECALCITOL; PROSTATE SPECIFIC ANTIGEN; TAXOID; VDR PROTEIN, HUMAN;

AGED; AGONISTS; BLOOD; CLINICAL TRIAL; DISEASE COURSE; GENETICS; HUMAN; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALKYNES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHOLECALCIFEROL; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, CALCITRIOL; TAXOIDS; TREATMENT OUTCOME;

EID: 84930910609     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3247     Document Type: Article

References (0)